Product Program year 2020 Source: CMS Open Payments

Durezol

Drug Ophthalmology

NDC 0065-9240-07

Open in the dashboard

General payments

$242,786

3,207 payments

Research payments

$0

0 payments

Through program year 2020, $242,786 in general payments and $0 in research payments were reported against Durezol (Ophthalmology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2020 General $923 27
2019 General $241,863 3,180

Breakdown

Who paid General payments · program years 2019–2020
  1. Novartis Pharmaceuticals Corporation $242,786 3,207 payments
Top recipients General payments · program year 2020
  1. Arthur Epstein Optometrist, Corneal and Contact Management · Phoenix, AZ $500 54% · 1 payment
  2. Carter Kirk Cornea and External Diseases Specialist · River Forest, IL $34 4% · 2 payments
  3. Robyn Glass Optometrist · Eustis, FL $30 3% · 1 payment
  4. Houman Vosoghi Glaucoma Specialist · Westlake Village, CA $27 3% · 1 payment
  5. Jennifer Tekiele Optometrist · Goodlettsville, TN $26 3% · 1 payment

The top 5 of 26 recipients; each share is of general payments naming this product in 2020.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2020
  1. Optometrist, Corneal and Contact Management Optometrist $500 55% · 1 practitioner
  2. Optometrist $263 29% · 15 practitioners
  3. Ophthalmology $37 4% · 3 practitioners
  4. Glaucoma Specialist Ophthalmology $37 4% · 2 practitioners
  5. Retina Specialist Ophthalmology $36 4% · 3 practitioners

The top 5 of 6 specialties; each share is of general payments naming this product to practitioners with a specialty in 2020. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2020
  1. Arizona $515 56% · 2 recipients
  2. California $131 14% · 8 recipients
  3. Florida $67 7% · 4 recipients
  4. Louisiana $62 7% · 3 recipients
  5. Illinois $47 5% · 2 recipients

The top 5 of 9 states; each share is of general payments naming this product in 2020 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

457

Prescriptions dispensed, refills included

Drug cost

$139,001

Paid at the pharmacy, in all

Prescribers

29

With 11 or more claims of it

Medicare Part D drugs matched to DUREZOL, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Durezol Difluprednate Same name 29 457 $139,001

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 29 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Joseph Sokol Ophthalmology CT 54 $11,726 None on record
Lorenzo Cervantes Ophthalmology CT 32 $6,999 None on record
Frederick Sauerburger Ophthalmology MD 24 $5,077 None on record
Cesar Samson Ophthalmology NY 20 $4,733 None on record
Sarah Nehls Ophthalmology WI 19 $16,234 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 29 with Patron
3,207 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2020

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record